The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.
 
Anna Maria Di Giacomo
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Immunocore; Immunocore; MSD Oncology; Pierre Fabre; Sanofi; Sun Pharma
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Matteo Simonelli
Consulting or Advisory Role - GlaxoSmithKline; Incyte; Naya Oncology
Travel, Accommodations, Expenses - Pfizer; Pfizer; Sanofi
 
Federica Santangelo
No Relationships to Disclose
 
Giovanni Amato
No Relationships to Disclose
 
Elena Simonetti
No Relationships to Disclose
 
Jill Graham
No Relationships to Disclose
 
Michael M. F. Lahn
Employment - iOnctura
Leadership - iOnctura
Stock and Other Ownership Interests - Incyte; iOnctura
 
Giusy Di Conza
Employment - iOnctura
Stock and Other Ownership Interests - iOnctura
 
Tracey Hammett
Employment - iOnctura
Stock and Other Ownership Interests - iOnctura
 
Rebeca Zorrilla
Employment - iOnctura
Stock and Other Ownership Interests - iOnctura
 
Marco Durini
Employment - Fortrea
Stock and Other Ownership Interests - Fortrea
 
Ziyang Tan
No Relationships to Disclose
 
Lakshmikanth Tadepally
Stock and Other Ownership Interests - Cytodelics
Consulting or Advisory Role - Health Advances
 
Petter Brodin
No Relationships to Disclose
 
Mariaelena Occhipinti
Employment - Radiomcs
Leadership - Radiomics
Stock and Other Ownership Interests - Radiomcs
 
Carmelo Carlo-Stella
No Relationships to Disclose
 
Armando Santoro
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Incyte; MSD; Pfizer; Sanofi; SERVIER
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Bayer; BMS; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda
 
Pavlina Spiliopoulou
Honoraria - Pfizer
Travel, Accommodations, Expenses - Eisai
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); CV6 Therapeutics (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); Seagen (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ewopharma (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CV6 Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Exscientia (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Moderna Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - iOnctura (Inst); Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Michele Maio
Stock and Other Ownership Interests - Epigen Therapeutics; Theravance
Honoraria - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Alfasigma; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Patents, Royalties, Other Intellectual Property - DNA Hypomethylating agents for cancer therapy
Travel, Accommodations, Expenses - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche